When people research fat loss and endurance compounds, the name Cardarine comes up quickly. And it usually comes with a question: is it a SARM, does it cause cancer, and does it actually do what people claim?
The short answer is that Cardarine, also known as GW 50156 or Endurobol, is a research compound with a genuinely interesting pharmacological profile. It is not a SARM. It works through a completely different mechanism, and the cancer question is more nuanced than the headlines suggest.
This guide covers what Cardarine is, how it works, what the research says about its benefits and risks, and everything you should understand before forming an opinion on it.
Cardarine is a synthetic compound originally developed in the 1990s through a collaboration between Ligand Pharmaceuticals and GlaxoSmithKline. The original research focus was the treatment of metabolic and cardiovascular diseases, including type 2 diabetes and dyslipidemia.
Despite being frequently grouped with SARMs in online communities, Cardarine is not a selective androgen receptor modulator. It is classified as a PPARdelta receptor agonist, which stands for peroxisome proliferator-activated receptor delta. The distinction matters because it means GW 50156 does not interact with androgen receptors at all. Its effects on energy metabolism and endurance operate through an entirely separate biological pathway.
After completing a significant number of preclinical trials, GlaxoSmithKline discontinued its development in 2007 following internal animal studies that showed accelerated tumor growth in rats. Despite that discontinuation, Cardarine was adopted by athletic and bodybuilding communities because of the pronounced endurance and fat loss effects observed in earlier research.
The World Anti-Doping Agency (WADA) subsequently added Cardarine and other PPARdelta agonists to its prohibited substances list, where it remains today.
GW 50156 binds to the PPARdelta receptor, a nuclear receptor protein found in skeletal muscle, the heart, and adipose tissue. When activated, this receptor influences gene expression in ways that shift how the body handles energy.
The two primary effects of this receptor activation are:
From a metabolic standpoint, this mirrors what happens during sustained low-intensity exercise or a strict ketogenic diet, but through direct receptor-level signaling rather than dietary restriction or physical adaptation. Scientists studying insulin resistance and metabolic syndrome have found this mechanism particularly relevant because of its potential effect on glucose regulation.
It is worth noting that because Cardarine is non-hormonal, it does not interact with the hypothalamic-pituitary-gonadal axis. There is no testosterone suppression, no estrogenic activity, and no need for post-cycle therapy.
Most of the available research on Cardarine comes from animal studies and a limited number of human trials. The findings are generally consistent, though it is important to frame them in their proper research context.
Animal studies showed that rats given GW 50156 demonstrated roughly 50 to 70 percent more endurance than control groups. The mechanism behind this is the shift toward fat oxidation as fuel, which conserves glycogen stores and delays the onset of fatigue.
In human reports, the increase in cardiovascular and aerobic capacity is described as noticeable within the first session after dosing. This is consistent with the rapid receptor-level changes that PPARdelta agonism produces in muscle tissue.
One clinical study examined Cardarine in 13 obese men with elevated body fat and an unhealthy lipid profile. At a dose as low as 2.5 mg per day, the compound reduced LDL cholesterol, triglycerides, and circulating fatty acids. Body composition improvements were also observed, though detailed body fat percentage data was not captured in the study’s primary endpoints.
The fat-burning effect stems from two reinforcing mechanisms: increased calorie expenditure during exercise due to higher oxidative capacity, and the baseline metabolic shift away from glucose utilization. The result in animal models was a roughly 5 percent greater reduction in body fat compared to control groups over comparable study periods.
Cardarine was originally developed with cardiovascular disease in mind, and that research direction produced some meaningful findings. Studies in animal models showed reductions in arterial plaque, improved blood vessel function, and reduced vascular inflammation. The human trials conducted in 2007, 2011, and 2012 noted positive changes in HDL cholesterol, LDL, and triglycerides, alongside improvements in insulin sensitivity.
The insulin sensitivity data is particularly relevant from a research standpoint because it connects directly to the PPARdelta mechanism and its influence on glucose metabolism. For researchers studying type 2 diabetes pathways, this remains one of the more scientifically interesting aspects of the compound.
Unlike many compounds studied in similar research contexts, Cardarine does not appear to be hepatotoxic. The human trials found no markers of liver damage at the doses studied. Research has also noted anti-inflammatory effects in liver tissue and potential protective effects on kidney function through inflammation reduction. This distinguishes it from many orally active compounds where hepatic strain is a documented concern.
This is the question most people come to with, and it deserves a thorough answer rather than a headline.
In 2007, GlaxoSmithKline conducted a long-term carcinogenicity study in rats that observed accelerated development of cancerous tumors. This study is the primary reason GW 50156 was discontinued and is frequently cited as proof that Cardarine causes cancer. But the full picture is more complicated.
The lowest dose at which tumor growth was observed in rats was 3 mg per day. When converted to a human equivalent dose using body surface area methodology from FDA draft guidelines, that rat dose translates to approximately 0.48 mg per kilogram of body weight per day. For an 85 kg person, that is roughly 40 mg per day. For a 90 kg person, it is approximately 43 mg per day.
This is approximately four times higher than the typical research dose range of 10 to 15 mg per day, not 50 to 100 times higher as some sources have claimed. The second critical factor is cycle duration. The 2007 study ran for 104 consecutive weeks, which is thirteen times longer than a standard 8-week research cycle.
A subsequent study examined Cardarine at doses equivalent to 154 mg per day for a 90 kg person, administered over a 7-day period. At this dramatically elevated dose over a short timeframe, no tumor development was observed and the compound actually demonstrated measurable anti-cancer activity. This finding suggests that cycle length may be the more significant variable in the carcinogenicity data, rather than dose alone.
As of 2026, there are no documented cases of cancer in humans linked to Cardarine use. That does not establish safety, since long-term human data simply does not exist. But it does mean the risk profile, while real and worth taking seriously, is not as straightforward as the 2007 discontinuation implied.
GW-501516 (Cardarine) from SwissChems comes in 60 capsules dosed at 10 mg each, third-party HPLC tested with published COAs so you know exactly what you’re getting. One of the more trusted sources for this compound, with a 36-month shelf life and a solid return policy if anything’s off.
Buy Now
Disclaimer: This product is for research purposes only. It is not intended for human consumption and has not been evaluated or approved by the FDA or any other regulatory authority.
Based on the available human trial data and the carcinogenicity research discussed above, the dosage range most frequently referenced in research contexts is 10 to 20 mg per day, with 8-week cycles being the most consistently cited duration.
The 2007, 2011, and 2012 human trials included groups receiving 10 mg per day for up to 12 weeks without observable adverse effects or liver changes. This is the closest thing to a studied human benchmark that exists, though it is worth emphasizing that these were clinical trials conducted under supervision, not general use protocols.
GW 50156 has a half-life of approximately 16 to 24 hours, which means once-daily dosing is sufficient to maintain relatively stable plasma levels. Some researchers have explored splitting the daily dose in half, taking one portion in the morning and one in the evening, on the basis that this may better match the compound’s variable half-life data.
Because Cardarine is non-hormonal, there is no suppression of natural testosterone and no post-cycle therapy required. This is one of the characteristics that distinguishes it from SARMs and oral anabolic steroids, both of which suppress the hypothalamic-pituitary-gonadal axis to varying degrees.
Because Cardarine is non-hormonal and does not interact with androgen receptors, it does not produce the same suppressive effects as SARMs. This means it can theoretically be combined with other research compounds without additive hormonal risk, though it is important to note that stacking any compounds introduces variables not accounted for in single-compound studies.
In research literature and user-documented protocols, Cardarine is most frequently paired with Ostarine (MK-2866) in cutting-oriented research designs, where the goal is preserving lean tissue while reducing fat. For lean mass-focused research designs, it has also been studied alongside LGD-4033 to complement the anabolic signaling with enhanced fat oxidation and cardiovascular output.
These combinations do not change Cardarine’s PCT requirements, since its non-hormonal mechanism remains unchanged regardless of what it is paired with.
Cardarine is legal to purchase and possess in most countries as a research chemical, with Australia being the primary exception. The Therapeutic Goods Administration (TGA) classifies it as a Schedule 9 prohibited substance, meaning it is illegal in Australia even with a prescription.
For competitive athletes, GW 50156 is on the banned substances lists of WADA, USADA, and ASADA. Detection in anti-doping testing can result in disqualification and suspension.
The most significant safety limitation remains the absence of long-term human data. The human trials that exist were short in duration and conducted at therapeutic research doses under clinical oversight. No large-scale, long-duration safety data in healthy populations exists, and the carcinogenicity findings from animal research, however context-dependent, have never been fully resolved with comparable human studies.
Anyone considering Cardarine should weigh the research-context benefits against this knowledge gap honestly, consult with a qualified healthcare provider, and verify legal compliance in their jurisdiction.
Cardarine is one of the more scientifically interesting research compounds in this space, in large part because it operates through a mechanism that most performance-focused compounds do not touch. Its effects on fat oxidation, endurance, cardiovascular markers, and insulin sensitivity are well-supported in animal studies and backed by limited but positive human trial data.
The cancer question is real but context-dependent. The data that exists points to extreme dose and extreme cycle length as the driving variables in tumor development, not short-term use at typical research ranges. That said, the absence of long-term human safety data means that question cannot be definitively resolved, and anyone engaging with this compound should approach it with that understanding.
What the research does make consistently clear is that Cardarine’s mechanism is distinct, its non-hormonal profile sets it apart from most compounds in similar research categories, and the scientific interest it generated, from GlaxoSmithKline to WADA, reflects something genuinely unusual in its pharmacological profile.
As with any research compound, understanding what you are looking at before forming conclusions matters more than the headline.
Frequently Asked Questions
Cardarine is a synthetic PPARdelta receptor agonist, not a SARM, developed in the 1990s by Ligand Pharmaceuticals and GlaxoSmithKline. It was originally studied for metabolic and cardiovascular disease applications. It is currently classified as a research compound and has not been approved for human use by the FDA or other regulatory authorities.
GW 50156 activates the PPARdelta receptor in skeletal muscle and fat tissue. This triggers a shift in energy metabolism away from glucose and toward fat oxidation, increasing muscle oxidative capacity and endurance output. It also influences gene expression pathways linked to lipid metabolism and insulin sensitivity.
A 2007 GlaxoSmithKline study observed accelerated tumor growth in rats at doses roughly four times the typical research range, over a 104-week period. Subsequent research at normal doses and standard cycle lengths did not replicate this finding and in some cases observed anti-cancer activity. As of 2026, there are no documented cases of cancer in humans linked to Cardarine. The risk remains poorly understood in long-term human use.
Cardarine is legal to purchase and use as a research chemical in most countries, with the exception of Australia where it is classified as a Schedule 9 prohibited substance. It is banned in all competitive sports governed by WADA, USADA, and ASADA. Legal status can change, so verifying current regulations in your country is always recommended.
No. Cardarine is non-hormonal and does not suppress the body’s natural testosterone production or interact with the hypothalamic-pituitary-gonadal axis. This distinguishes it from SARMs and anabolic steroids, both of which typically require post-cycle therapy to restore hormonal function.
DISCLAIMER: The information provided above is not intended to substitute professional medical advice, diagnosis, or treatment. Always seek your physician’s advice or another qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have seen or read.We bear no responsibility or liability for your use of any compound.
